Login to Your Account

As biosimilars improve access to biologics, policies need to align

By Nuala Moran
Staff Writer

Wednesday, September 13, 2017

LONDON – Governments across Europe have realized that biosimilars need a tailor-made framework and are disentangling their pricing policies from those applied to generic medicines, according to a review of policies in 31 countries.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription